Oncothyreon

Contact
oncothyreon.com
+1425450-0370

Oncothyreon Inc.

110-110th Avenue NE, Suite 685
98004 Bellevue
USA
+1425450-0370
oncothyreon.com
Contact
Profile Products News
Contact

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Read more about Oncothyreon
Facts about Oncothyreon
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Oncothyreon

Product portfolio

Show all

News about Oncothyreon

Oncothyreon

20-Jun-2008 | research and development

Oncothyreon initiates Phase 1 trial of PX-866 cancer compound

Oncothyreon Inc. announced enrollment of the first patient in a Phase 1 trial of PX-866 in patients with advanced solid tumors. PX-866 is a small molecule ...

Read news
Oncothyreon

16-Jun-2008 | research and development

Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer

Oncothyreon Inc. announced that the first patient has been treated in a Phase 1b clinical trial of PX-12 in patients with advanced metastatic cancer. PX-12 ...

Read news
Oncothyreon

16-May-2008 | research and development

Oncothyreon to receive milestone payment from Merck KGaA

Oncothyreon Inc. announced that it has completed the transfer of certain assays and manufacturing technology related to Stimuvax(R) (BLP25 liposome vaccine ...

Read news
Oncothyreon

27-Mar-2008 | research and development

Oncothyreon announces issuance of patent for PX-867

Oncothyreon Inc. announced that the U.S. Patent and Trademark office has issued a patent for PX-867, a small molecule compound currently in preclinical ...

Read news
Oncothyreon

27-Feb-2008 | research and development

Oncothyreon's PX-478 is effective in preclinical model of human lung cancer

Oncothyreon Inc. announced the presentation of data demonstrating the effectiveness of PX-478 in a preclinical model of human lung cancer at the 8th Annual ...

Read news
Show more news about Oncothyreon

Here you will find Oncothyreon Inc.